Phase I trial of carboplatin and weekly paclitaxel in patients with advanced non-small-cell lung cancer

Japanese Journal of Clinical Oncology

Volumn 34, Issue 9, 2004, Pages 505-509

  Kikuchi, Junko ^a   Yamazaki, Koichi ^a   Kinoshita, Ichiro ^b   Asahina, Hajime ^a   Imura, Mikado ^a   Kikuchi, Eiki ^a   Konishi, Jun ^a   Shinagawa, Naofumi ^a   Oki, Hiromitsu ^c   Dosaka Akita, Hirotoshi ^b   Nishimura, Masaharu ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carboplatin; Non small cell lung cancer; Paclitaxel; Phase I study

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG DISPOSITION; DRUG TOLERABILITY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION COMPLICATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PNEUMONIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; ADENOCARCINOMA; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; SQUAMOUS CELL CARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PACLITAXEL;

EID: 7944237309     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyh093     Document Type: Article

References (19)

1. Manfredi JJ, Parness J, Horwitz SB. Taxol binds to cellular microtubules. J Cell Biol 1989;94:688-96.
2. Belotti D, Vergani V, Drudis T, et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996;2:1843-9.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8.
4. Kelly K, Crowley J, Bunn PA, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer: A Southwest Oncology Group Trial. J Clin Oncol 2001;19:3210-8.
5. Belani CP, Natale RB, Lee JS. Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 1998;17:455a (Abstr 1751).
6. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trail for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003;21:2933-9.
7. Hirabayashi M, Okuda M, Endo K, et al. Dose finding study of carboplatin and weekly paclitaxel for advanced non-small cell lung cancer. JJLC 2001;41:767-72 (in Japanese).
8. National Cancer Institute-Common Toxicity Criteria (NCI-CTC) Version 2.0. April 30, 1999.
9. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: WHO, 1979.
10. Akerley W III, Glantz M, Choy H. Preliminary results of a phase I study of weekly pacitaxel infusion in patients with non-small cell lung cancer. Semin Oncol 1996;23:14-8.
11. Lopes NM, Adams EG, Pitts TW, et al. Cell kill kinetics and cell cycles effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993;32:235-42.
12. Jordan MA, Wendell K, Gardiner S, Derry WB, Copp H, Wilson L. Mitotic block induced in HeLa cells by low concentration of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. Cancer Res 1996;56:816-25.
13. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995;13:180-90.
14. Seidman AD, Hudis CA, Albanel J, et al. Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer. J Clin Oncol 1998;16:3353-6.
15. Gilewski T, Norton L. Cytokinetics and breast cancer chemotherapy. Disease of the Breast. Philadelphia, PA: Lippincott-Raven, 1996; 751-68.
16. Akerley W, Glantz M, Choy H, et al. Phase I trial of weekly paclitaxel in advanced lung cancer. J Clin Oncol 1998;16:153-8.
17. Fennelly D, Aghajanian C, Shapiro F, et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 1997;15:187-92.
18. Marchetti P, Urien S, Cappellini GA, Ronzino G, Ficorella C. Weekly administration of paclitaxel: Theoretical and clinical basis. Crit Rev Oncol Hematol 2002;44:S3-13.
19. Rowinsky EK, Donehower RC. Drug therapy: Paclitaxl (Taxol). N Engl J Med 1995;332:1004-14.